|

Trastuzumab+Pertuzumab Clinical Trials

7 actively recruiting trials across 1 location

▲ +2 trials since June 2026

Also known as: Herceptin, Herceptin + Perjeta, Phesgo

Pipeline

Phase 2: 3Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Seoul National University Bundang Hospital1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Massachusetts General Hospital1
  • Jiangsu HengRui Medicine Co., Ltd.1
  • Henan Cancer Hospital1

Indications

Other6 trials

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Phase 1/2
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Phase 3
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
Phase 2
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Phase 2
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Boston, Massachusetts1 trial

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Massachusetts General Hospital

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.